Experience

Davis Polk advised InflaRx N.V. on its $100 million initial public offering of 6,667,000 of its common shares. In addition, InflaRx has granted the underwriters a 30-day option to purchase…

Davis Polk is advising McKesson Corporation on its acquisition of RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health…

Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of Allena Pharmaceuticals, Inc., at $14.00 per share, for total gross…

Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230 million of its ordinary shares in the form of American Depositary…

Davis Polk advised the underwriters in connection with an initial public offering of 7,500,000 shares of common stock of Deciphera Pharmaceuticals, Inc., at $17.00 per share, for total…

Davis Polk advised the joint book-running managers and representatives of the underwriters on the $172.5 million initial public offering by Zai Lab Limited of 9,583,333 American…

Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. as a minority…

Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of Sienna Biopharmaceuticals, Inc., including shares sold pursuant to…

Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The…

Davis Polk is advising Mitsubishi Tanabe Pharma Corporation on its approximately $1.1 billion acquisition of NeuroDerm Ltd. The transaction, which is expected to close in the fourth quarter…